Patents Examined by Carmencita M Belei
  • Patent number: 10935548
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: March 2, 2021
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 10899845
    Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: January 26, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 10866247
    Abstract: The present invention relates in essence to an in vitro method for determining the stability, such as the shelf stability; stability over time; shelf life of a composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, said method comprising the steps of contacting a surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of aggregated human IgG; contacting said surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of said composition of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB; determining the amount of aggregated human IgG which is bound to said surface comprising said human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, and comparing the amount of aggregated human IgG which is bound to said surface as determined in step (c) with a reference value and (thereby) determining the stability [shelf stability; stability over time; shelf life] of said composition which comprises or
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: December 15, 2020
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl, Dominik Ter Meer
  • Patent number: 10794912
    Abstract: An immunoadsorbent for purifying fumonisin B1, aflatoxin B1, ochratoxin A, zearalenone and sterigmatocystin; a complex affinity column and its preparation method; and a method for detecting the mycotoxins using the same are provided. The immunoadsorbent comprises a solid-phase support, and an anti-fumonisin B1 monoclonal antibody, an anti-aflatoxin B1 monoclonal antibody, an anti-ochratoxin A monoclonal antibody, an anti-zearalenone monoclonal antibody and an anti-sterigmatocystin monoclonal antibody which are coupled to the solid-phase support, wherein the anti-fumonisin B1 monoclonal antibody is secreted by a hybridoma cell strain Fm7A11. The complex affinity column can be used for purification and detection of a fumonisin B1 sample, an aflatoxin B1 sample, an ochratoxin A sample, a zearalenone sample and a sterigmatocystin sample at the same time.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: October 6, 2020
    Inventors: Zhaowei Zhang, Peiwu Li, Qi Zhang, Xiaofeng Hu, Wen Zhang
  • Patent number: 10788494
    Abstract: Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: September 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Feny Gunawan, Yi-Chun Hsiao, Denise C. Krawitz, Margaret S. Lin, Martin Vanderlaan, Rajesh Vij, Inn H. Yuk, Judith Zhu-Shimoni
  • Patent number: 10690681
    Abstract: The present invention provides an accurate and reliable method to detect acute cardiovascular syndromes or disorders and to detect acute cardiovascular syndromes or disorders at earlier time points such that more aggressive interventions can be used in high risk subjects
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 23, 2020
    Assignee: Washington University
    Inventors: Walter A. Boyle, Richard Bach
  • Patent number: 10684283
    Abstract: This disclosure relates to the field of diagnostic methods. A new marker antibody for rheumatoid arthritis, as well as a new method for detecting rheumatoid arthritis, is disclosed herein. Also provided herein are means and methods for predicting whether a subject will develop rheumatoid arthritis. This disclosure is based on the discovery that patients with rheumatoid arthritis have antibodies in their circulation that react specifically with citrullinated antibodies. In one aspect, the disclosure, therefore, relates to an antibody comprising a citrulline residue. In another aspect, the disclosure provides a method for the detection of antibodies specific for rheumatoid arthritis in a sample from a subject, wherein the sample is contacted with a citrullinated antibody and wherein it is determined whether the sample comprises antibodies specifically reactive with the citrullinated antibody.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: June 16, 2020
    Assignee: NOVIO TH B.V.
    Inventor: Martinus Hubertus Leonardus Salden
  • Patent number: 10684285
    Abstract: The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: June 16, 2020
    Assignee: KAIVOGEN OY
    Inventors: Kim Pettersson, Kamlesh Gidwani
  • Patent number: 10670612
    Abstract: The present invention provides novel compositions and methods for creating quantitative standards to calibrate analytes. These compositions and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers. Also provided are kits comprising the novel compositions for use in assays, for example sandwich immunoassays.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: June 2, 2020
    Inventors: Paul Rhyne, Claudio Mapelli, Oitak Allen Wong, Flora Berisha, Robert John Neely
  • Patent number: 10620216
    Abstract: The present invention concerns a method for determining the concentration of a protein in a gastrointestinal (GI) tract sample taken from a human or an animal. The present invention is characterized by the feature that a dilution of the sample in the buffered aqueous extraction medium in a range of 1:100 to 1:10,000 is obtained. The present invention leads to a significant improvement of the technical situation, and provides a simple, sensitive and specific determination tool of proteins in GI tract samples. The determination of proteins, e.g. calprotectin, elastases or hemoglobin, in GI tract samples leads to more accurate and reproducible results.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: April 14, 2020
    Inventors: Jakob Weber, Marie-Eve Überschlag, Marianne Prica, Thomas Jermann
  • Patent number: 10613101
    Abstract: A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n=224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n=116; p=0.915).
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 7, 2020
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher, Heinz Jürgen Roth
  • Patent number: 10591494
    Abstract: The invention relates to an in vitro diagnosis device (10) for the detection of at least one reaction between an erythrocytic phenotype antigen and an antibody specifically directed against said antigen in a sample of blood or one of the components thereof. The device is characterized in that it comprises: a substrate (12); and a hydrophobic porous membrane (14) having a thickness of between 0.5 mm and 1.5 mm and a pore diameter of between 2 and 30 ?m, said membrane comprising at least one hydrophilic reaction zone (16) intended to receive the sample. The invention also relates to the uses of said device in immunohematology.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 17, 2020
    Assignee: Diagast
    Inventors: Najim Chaibi, Sylvain Malgouries, Megumi Lucas
  • Patent number: 10590188
    Abstract: The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: March 17, 2020
    Assignee: Queen Mary University of London
    Inventors: Michele Bombardieri, Constantino Pitzalis, Elisa Corsiero
  • Patent number: 10569270
    Abstract: Methods are provided for the large-scale high-content analysis of biological samples. In some embodiments, the methods are implemented in a reversed open microwell system that includes an array of open microwells, at least one microchannel, at least one input port and at least one output port. In certain embodiments, the reversed open microwell system can be inserted in an automated management system which includes an incubator at controlled temperature, humidity and CO2 levels, a fluid dispensing system, and is capable of phase-contrast and fluorescence image acquisition. Also provided are kits for introducing fluids into a microfluidic device, and systems for discharging one or more fluids in a microfluidic device.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: February 25, 2020
    Assignee: CELLPLY S.R.L.
    Inventors: Massimo Bocchi, Andrea Faenza, Laura Rocchi, Dario Biscarini, Nicola Pecorari
  • Patent number: 10551376
    Abstract: Systems, methods, and devices for selective capture and release of target particles, e.g., living cells, from liquid samples, e.g., blood, are provided. The particle capture systems include a substrate; a first layer of gelatin bound to the substrate by physical adsorption, wherein the gelatin is functionalized with a plurality of first members of a binding pair; a second layer of gelatin wherein the gelatin is functionalized with a plurality of the first members of the binding pair and the second layer is bound to the first layer via a plurality of second members of the binding pair that are associated with the first members of the binding pair on both the first and the second layers; and a plurality of nanostructures bound to the second members of the binding pair and to one or more particle-binding moieties that selectively bind to the target particles.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: February 4, 2020
    Assignee: The General Hospital Corporation
    Inventors: Eduardo Reategui, Shannon Stott, Mehmet Toner
  • Patent number: 10534007
    Abstract: The present invention provides a method for the assay of synucleins in a body fluid or tissue sample, wherein said method comprises the steps of contacting said sample with membrane lipids under conditions enabling binding of the synuclein to said lipids, and the detection of the lipid-bound synuclein by a synuclein-binding agent.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: January 14, 2020
    Inventor: Ronit Sharon
  • Patent number: 10502741
    Abstract: The present invention provides means and methods for selectively detecting activated MALT1 in a sample. Moreover, the present invention provides a method for diagnosing diseases, which are characterized by an increased MALT1 activity. Finally, the present invention provides methods for identifying patients which are amenable to treatment with a therapeutic agent capable of inhibiting MALT1 activity.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: December 10, 2019
    Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umweld (GmbH), Technische Universität München
    Inventors: Daniel Krappmann, Andrea Eitelhuber, Steven Verhelst
  • Patent number: 10502740
    Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: December 10, 2019
    Assignee: Mologic Limited
    Inventor: Paul James Davis
  • Patent number: 10502734
    Abstract: The present invention relates to a system for biodetection applications comprising two basic elements, a substrate with a functionalized surface and a nanoparticle, the system being capable of enhancing the plasmonic effect of the nanoparticle. The invention also relates to a biosensor incorporating such system, in addition to the method for detecting and quantifying a target analyte selected in a sample using such system. Finally, the invention relates to a device which can detect the enhanced optoplasmonic effect of the nanoparticles by means of the system of the invention or by combining the detection of such optoplasmonic effect with the analysis of the changes in the mechanical characteristics in the substrate.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: December 10, 2019
    Inventors: Francisco Javier Tamayo de Miguel, Priscila Monteiro Kosaka, Valerio Pini, Montserrat Calleja Goméz, Jose Jaime Ruz Martinez, Daniel Ramos Vega, Maria Ujue Gonzalez Sagardoy
  • Patent number: 10471086
    Abstract: The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 12, 2019
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: Salim Merali, Steven G. Kelsen, Carlos A. Barrero